Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 9/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ME2 | P23368 | 1/20 | 0.38 |
| ▸ | ME1 | P48163 | 1/20 | 0.38 |
| ▸ | ME3 | Q16798 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6451232 | 0.90 | LSS (0.76) | LSSALDH1A1POLBL3MBTL1MEN1 | |
| SCHEMBL5036103 | 0.88 | LSS (0.47) | LSSHPGDALDH1A1POLBGFER | |
| SCHEMBL5035569 | 0.87 | LSS (0.46) | LSSHPGDALDH1A1POLBGFER | |
| SCHEMBL5043394 | 0.86 | LSS (0.80) | LSSPOLBMEN1KMT2A | |
| SCHEMBL5043446 | 0.85 | LSS (0.61) | LSSHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL5038804 | 0.85 | LSS (0.43) | LSSHPGDALDH1A1POLBGFER | |
| SCHEMBL6450147 | 0.84 | LSS (0.62) | LSSMEN1KMT2A | |
| SCHEMBL5039272 | 0.84 | LSS (0.42) | LSSHPGDALDH1A1POLBGFER | |
| SCHEMBL5039073 | 0.81 | ALDH1A1 (0.40) | LSSHPGDALDH1A1POLBGFER | |
| SCHEMBL5133317 | 0.80 | LSS (0.44) | LSSHPGDALDH1A1POLBGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317432-B1 | PIPERIDINE DERIVATIVES FOR USE AS 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | disclosed |
| US-6964974-B2 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-11-15 | — | — | US | disclosed |
| US-20020068753-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068753-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | LSS 2/4885HPGD 43/4885ALDH1A1 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.